Advertisement

Pharmaceutical Medicine

, Volume 26, Issue 6, pp 411–420 | Cite as

Forum

Update
  • 22 Downloads

1. WHO Pilots Surveillance System Targeting Fake Medicines

A WHO project team has proposed pilot studies in Europe and the Western Pacific, aimed at establishing a system for surveillance and monitoring of substandard, spurious, falsely labelled, falsified and counterfeit medicines (SSFFC).

Minutes from the ninth meeting of the WHO Advisory Committee on Safety of Medicinal Products, held in May 2012, were published in the latest WHO Pharmaceuticals Newsletter. At the meeting, the WHO SSFFC Global Surveillance and Monitoring Project team presented examples of falsely labelled products, products intended to deceive with little or no active pharmaceutical ingredients and substandard products with specific contaminants. The team suggested that it was important to raise awareness of these issues, without providing information that would unintentionally assist those engaged in the illicit activities.

To assist with the project, the Uppsala Monitoring Centre (UMC) have agreed to develop a...

References

References

  1. World Health Organisation. Ninth meeting of the WHO Advisory Committee on Safety of Medicinal Products. WHO Pharmaceuticals Newsletter 2012 (4): 29–33Google Scholar

References

  1. Therapeutic Goods Administration. Early warning of safety issues with therapeutic products [media release]. 2012 Aug 30 [online]. Available from URL: http://www.tga.gov.au [Accessed 2012 Sept 12]

References

  1. European Medicines Agency. European Medicines Agency explains EU incident management plan for human medicines [media release]. 2012 Aug 13 [online]. Available from URL: http://www.ema.europa.eu/ [Accessed 2012 Sept 12]

References

  1. Pharmaceuticals and Medical Devices Agency. Launch of the pilot program of Direct Patient Reporting System for Adverse Drug Reactions. Pharmaceuticals and Medical Devices Safety Information 2012 (292): 5–7 [online]. Available from URL: http://www.pmda.go.jp [Accessed 2012 Sept 12]Google Scholar

References

  1. 1.
    Danish Health and Medicines Authority. Drug Analysis Prints involving data from more than 14,000 Danish adverse reaction reports available at the Danish Health and Medicines Authority’s website [media release]. 24 May 2012 [online]. Available from URL: http://laegemiddelstyrelsen.dk [Accessed 2012 Sept 12]
  2. 2.
    Parliamentary Secretary for Health and Ageing. On-line TGA database provides information on adverse reactions to medicines [media release]. 1 Aug 2012 [online]. Available from URL: http://www.health.gov.au [Accessed 2012 Sept 12]

References

  1. McMorran M, Rodrigues D. Adverse reaction and incident reporting: 2011. Canadian Adverse Reaction Newsletter 2012; 22 (3): 3–5 [online]. Available from URL: http://www.hc-sc.gc.ca [Accessed 2012 Sept 12]Google Scholar

References

  1. European Medicines Agency. Two further modules on good pharmacovigilance practices released for public consultation [media release]. 2012 Jul 26 [online]. Available from URL: http://www.ema.europa.eu/ [Accessed 2012 Oct 8]

References

  1. Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012; 486: 361–8PubMedGoogle Scholar

References

  1. 1.
    Bourgeois FT, Murthy S, Pinto C, et al. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics 2012; 130 (2): 285–92PubMedCrossRefGoogle Scholar
  2. 2.
    Boston Childrens Hospital. Drug safety and efficacy in children is rarely addressed in drug trials for major diseases [media release]. 2012 Jul 23 [online]. Available from URL: http://www.childrenshospital.org [Accessed 2012 Sept 12]

References

  1. 1.
    Therapeutic Goods Administration. Interpreting information on the Database of Adverse Event Notifications [media release]. 2012 Aug 3 [online]. Available from URL: http://www.tga.gov.au [Accessed 2012 Sept 12]
  2. 2.
    Bita N. 10 deaths linked to anti-flu vaccines. 2012 Aug 3 [online]. Available from URL: http://www.theaustralian.com.au [Accessed 2012 Sept 12]

References

  1. UK Department of Health. Joint DH/ABPI statement on arrangements for pricing branded medicines from 2014 [media release]. 2012 Aug 10. Available from URL: http://www.dh.gov.uk [Accessed 2012 Sept 12]

References

  1. Megget K. Per capita income-linked reference pricing planned for India. 2012 Aug 20 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2012 Sept 12]

References

  1. UK Department of Health. NICE to assess high cost low volume drugs [media release]. 2012 Jul 19 [online]. Available from URL: http://www.dh.gov.uk [Accessed 2012 Sept 12]

References

  1. Jha AK, Aubert RE, Yao J, et al. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Affairs 2012; 31 (8): 1836–46PubMedCrossRefGoogle Scholar

References

  1. Sheldon T. Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs. BMJ 2012; 345: e5461PubMedCrossRefGoogle Scholar

References

  1. BioTrends Research Group. Biosimilar manufacturers must offer a 26 percent lower price tag than the reference brand to be reimbursed by US managed care organizations [media release]. 2012 Jul 24 [online]. Available from URL: http://www.decisionresourcesgroup.com [Accessed 2012 Sept 12]

References

  1. Moszynski P. Defeat of antipiracy treaty is hailed as victory for generic drugs. BMJ 2012; 345: e4660PubMedCrossRefGoogle Scholar

References

  1. 1.
    Molife LR, Alam S, Olmos D, et al. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann Oncol 2012; 23 (8): 1968–73PubMedCrossRefGoogle Scholar
  2. 2.
    Wheler JJ, Tsimberidou AM, Hong DS, et al. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol 2012; 23 (8): 1963–7PubMedCrossRefGoogle Scholar
  3. 3.
    Greystoke A, Ranson M. Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents. Ann Oncol 2012; 23(8): 1934–6PubMedCrossRefGoogle Scholar

References

  1. Hoffman KB, Kraus C, Dimbil M, et al. A survey of the FDA’s AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One 2012; 7 (8): e42866PubMedCrossRefGoogle Scholar

References

  1. 1.
    Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. Epub 2012 May 7Google Scholar
  2. 2.
    Centre for Addiction and Mental Health. Genetic link to rapid weight gain from antipsychotics discovered [media release]. 2012 Jul 17 [online]. Available from URL: http://www.camn.ca [Accessed 2012 Sept 12]
  3. 3.
    Chowdhury NI, Tiwari AK, Souza RP, et al. Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. Pharmacogenomics J. Epub 2012 Feb 7Google Scholar

References

  1. 1.
    Lavoie Smith EM, Pang H, Cirrincione C, et al. CALGB 170601: a phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN) [abstract no. CRA9013]. 48th Annual Meeting of the American Society of Clinical Oncology. 2012 Jun 1–5 [online]. Available from URL: http://abstract.asco.org/abstview%5f114%5f91721.html [Accessed 2012 Sep 12]
  2. 2.
    Mamtani R, Haynes K, Bilker WB, et al. Long-term therapy with thiazolidinediones and the risk of bladder cancer: a cohort study [abstract no. 1503]. 48 th Annual Meeting of the American Society of Clinical Oncology. 2012 Jun 1–5 [online]. Available from URL: http://abstract.asco.org/abstview%5f114%5f91721.html [Accessed 2012 Sep 12]
  3. 3.
    Khan QJ, Kimler BF, Reddy PS, et al. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: the VITAL trial [abstract no. 9000]. 48th Annual Meeting of the American Society of Clinical Oncology. 2012 Jun 1–5 [online]. Available from URL: http://abstract.asco.org/abstview%5f114%5f91721.html [Accessed 2012 Sep 12]
  4. 4.
    Moinpour C, Berry DL, Ely B, et al. Preliminary quality-of-life outcomes for SWOG-9346: intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)-Phase III [abstract no. 4571]. 48th Annual Meeting of the American Society of Clinical Oncology. 2012 Jun 1–5 [online]. Available from URL: http://abstract.asco.org/abstview%5f114%5f91721.html [Accessed 2012 Sep 12]
  5. 5.
    Nekhlyudov L, Aziz N, Lerro CC, et al. Oncologists and primary care providers awareness of late effects of cancer treatment: implications for survivorship care [abstract no. 6008]. 48th Annual Meeting of the American Society of Clinical Oncology. 2012 Jun 1–5 [online]. Available from URL: http://abstract.asco.org/abstview%5f114%5f91721.html [Accessed 2012 Sep 12]

References

  1. 1.
    Mills F, Ford N, Nachega J, et al. Earlier initialization of antiretroviral therapy is associated with long-term survival and is cost-effective: findings from a deterministic model of a large Ugandan cohort [abstract no. MOPE763]. 19th International AIDS Conference; 2012 Jul 22–27 [online]. Available from URL: http://pag.aids2012.org/Abstracts.aspx?AID=10098 [Accessed 2012 Sep 12]
  2. 2.
    Sempa J, Ssennono M, Kuznik A, et al. Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda [abstract no. THPE663]. 19th International AIDS Conference; 2012 Jul 22–27 [online]. Available from URL: http://pag.aids2012.org/Abstracts.aspx?AID=8830 [Accessed 2012 Sep 12]
  3. 3.
    Walensky RP, Ross EL, Kumarasamy N, et al. The cost-effectiveness of treatment as prevention: analysis of the HPTN 052 trial [abstract no. FRLBC01]. 19th International AIDS Conference; 2012 Jul 22–27 [online]. Available from URL: http://pag.aids2012.org/Abstracts.aspx?AID=21242 [Accessed 2012 Sep 12]
  4. 4.
    El-Adas A, Amenyah R, Koleros A, et al. Economic evaluation of the national program to prevent mother-to-child transmission of HIV in Ghana [abstract no. FRAE0103]. 19th International AIDS Conference; 2012 Jul 22–27 [online]. Available from URL: http://pag.aids2012.org/Abstracts.aspx?AID=12065 [Accessed 2012 Sep 12]
  5. 5.
    Kuznik A, Lamorde M, Hermans S, et al. Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda [abstract no. THPE662]. 19th International AIDS Conference; 2012 Jul 22–27 [online]. Available from URL: http://pag.aids2012.org/Abstracts.aspx?AID=8505 [Accessed 2012 Sep 12]
  6. 6.
    Revill P, Sculpher M, Walker S, et al. The cost-effectiveness of maternal and infant antiretroviral regimens to prevent vertical HIV transmission in Malawi [abstract no. FRAE0102]. 19th International AIDS Conference; 2012 Jul 22–27 [online]. Available from URL: http://pag.aids2012.org/Abstracts.aspx?AID=16525 [Accessed 2012 Sep 12]
  7. 7.
    Dancel E, Ashigbie P. Transition from stavudine to tenofovir and zidovudine for first-line treatment of HIV/AIDS in low- and middle-income countries [abstract no. MOAE0205]. 19th International AIDS Conference; 2012 Jul 22–27 [online]. Available from URL: http://pag.aids2012.org/Abstracts.aspx?AID=7734 [Accessed 2012 Sep 12]

Copyright information

© Springer International Publishing AG 2012

Personalised recommendations